15_Trial

The chart shows the growth of an initial investment of $10,000 in 15_Trial, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Apr 14, 2021, 15_Trial's average daily return is +0.07%, while the average monthly return is +1.46%. At this rate, an investment would double in approximately 4.0 years.

Historically, 48% of months were positive and 52% were negative. The best month was Jan 2023 with a return of +29.6%, while the worst month was Apr 2022 at -19.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, 15_Trial closed higher 51% of trading days. The best single day was Apr 9, 2025 with a return of +15.5%, while the worst single day was Feb 3, 2022 at -8.8%.

15_Trial has an annualized alpha of -4.00%, beta of 1.76, and R2 of 0.68 versus S&P 500 Index. Calculated based on daily prices since April 14, 2021.

• This portfolio captured 173.96% of S&P 500 Index gains and 155.29% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• This portfolio had an annualized alpha of -4.00% versus S&P 500 Index - delivering less than market exposure alone would predict.
• Beta of 1.76 means this portfolio moves significantly more than S&P 500 Index - expect amplified gains in rallies and amplified losses in downturns.

15_Trial has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

15_Trial ranks 14 for risk / return — in the bottom 14% of Portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

The current 15_Trial Sharpe ratio is 1.01 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.53 to 2.41, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests weaker risk-adjusted returns than most portfolios, possibly due to lower returns, higher volatility, or both. It may be worth reviewing the allocation. You can use the Portfolio Optimization tool to explore options for improving the Sharpe ratio.

The chart below shows the rolling Sharpe ratio of 15_Trial compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

15_Trial provided a 0.15% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the 15_Trial. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 15_Trial was 62.58%, occurring on Dec 28, 2022. Recovery took 284 trading sessions.

The current 15_Trial drawdown is 6.11%.

The chart below shows the rolling one-month volatility.